User profiles for Jeffrey M. Drazen
Jeffrey M. DrazenProfessor, Harvard Medical School Verified email at nejm.org Cited by 74582 |
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
JM Drazen, CN Yandava, L Dubé, N Szczerback… - Nature …, 1999 - nature.com
Clinically similar asthma patients may develop airway obstruction by different mechanisms 1,
2. Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway 3, …
2. Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway 3, …
The biology of nitrogen oxides in the airways.
Nitrogen oxides (NOx), regarded in the past primarily as toxic air pollutants, have recently
been shown to be bioactive species formed endogenously in the human lung. The relationship …
been shown to be bioactive species formed endogenously in the human lung. The relationship …
Mechanotransduction through growth-factor shedding into the extracellular space
Physical forces elicit biochemical signalling in a diverse array of cells, tissues and organisms
1 , 2 , 3 , helping to govern fundamental biological processes. Several hypotheses have …
1 , 2 , 3 , helping to govern fundamental biological processes. Several hypotheses have …
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma
Background Inhaled β-agonists are the most commonly used treatment for asthma, but data
suggest that regularly scheduled use of these agents may have a deleterious effect on the …
suggest that regularly scheduled use of these agents may have a deleterious effect on the …
Global strategy for asthma management and prevention: GINA executive summary
Asthma is a serious health problem throughout the world. During the past two decades, many
scientific advances have improved our understanding of asthma and ability to manage and …
scientific advances have improved our understanding of asthma and ability to manage and …
Treatment of asthma with drugs modifying the leukotriene pathway
In 1979 and 1980, the chemical structures of the material previously known as slow-reacting
substance of anaphylaxis were elucidated as 5(S)- hydroxy- 6(R)-glutathionyl- 7,9-trans-11,…
substance of anaphylaxis were elucidated as 5(S)- hydroxy- 6(R)-glutathionyl- 7,9-trans-11,…
Clinical trial registration: a statement from the International Committee of Medical Journal Editors
C De Angelis, JM Drazen, FA Frizelle, C Haug, J Hoey… - The Lancet, 2004 - thelancet.com
In today’s Lancet, the INTERHEART study investigators report a well-coordinated study of
risk factors for myocardial infarction in multiple populations. They present hazard ratios and …
risk factors for myocardial infarction in multiple populations. They present hazard ratios and …
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …
updated evidence-based strategy for asthma management and prevention, which can be …
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro.
JM Drazen, KF Austen, RA Lewis… - Proceedings of the …, 1980 - National Acad Sciences
The pharmacologic activities of leukotrienes C-1 and D(LTC-1 and LTD), constituents of slow
reacting substance of anaphylaxis (SRS-A), were evaluated in vitro on airway contractile …
reacting substance of anaphylaxis (SRS-A), were evaluated in vitro on airway contractile …
Artificial intelligence and machine learning in clinical medicine, 2023
CJ Haug, JM Drazen - New England Journal of Medicine, 2023 - Mass Medical Soc
AI and Machine Learning in Clinical Medicine, 2023 This first article in a series describes the
history of artificial intelligence in medicine; the use of AI in image analysis, identification of …
history of artificial intelligence in medicine; the use of AI in image analysis, identification of …